Understanding anti-TNF treatment failure: does serum triiodothyronine-to-thyroxine (T3/T4) ratio predict therapeutic outcome to anti-TNF therapies in biologic-naïve patients with active luminal Crohn's disease?

"data s1 click here for additional data file."

"CONFLICT OF INTEREST Dr. Lin reports non‐financial support from Pfizer, non‐financial support from Ferring, outside the submitted work. Dr. Kennedy reports grants from F. Hoffmann‐La Roche AG, grants from Biogen Inc, grants from Celltrion Healthcare, grants from Galapagos NV, non‐financial support from Immundiagnostik, grants and non‐financial support from AbbVie, grants and personal fees from Celltrion, personal fees and non‐financial support from Janssen, personal fees from Takeda, personal fees and non‐financial support from Dr Falk, outside the submitted work. Prof. Ahmad reports grants and non‐financial support from F. Hoffmann‐La Roche AG, grants from Biogen Inc, grants from Celltrion Healthcare, grants from Galapagos NV, non‐financial support from Immundiagnostik, personal fees from Biogen inc, grants and personal fees from Celltrion Healthcare, personal fees and non‐financial support from Immundiagnostik, personal fees from Takeda, personal fees from ARENA, personal fees from Gilead, personal fees from Adcock Ingram Healthcare, personal fees from Pfizer, personal fees from Genentech, non‐financial support from Tillotts, outside the submitted work. Dr Selinger has received unrestricted research grants from Warner Chilcott, Janssen and AbbVie, has provided consultancy to Warner Chilcott, Dr Falk, AbbVie, Takeda, Fresenius Kabi, Arena, Galapagos, Celltrion, Norgine and Janssen, and had speaker arrangements with Warner Chilcott, Norgine, Galapagos, Fresenius Kabi, Celtrion, Dr Falk, AbbVie, MSD, Pfizer and Takeda. Dr. Goodhand reports grants from F. Hoffmann‐La Roche AG, grants from Biogen Inc, grants from Celltrion Healthcare, grants from Galapagos NV, non‐financial support from Immundiagnostik, outside the submitted work. The following authors have nothing to declare: Neil Chanchlani, Isabel Carbery, Malik Janjua, Rachel Nice, Timothy J McDonald and Claire Bewshea."

"Laboratory tests were undertaken by the Exeter Blood Sciences Laboratory at the Royal Devon and Exeter (RD&E) NHS Trust (https://www.exeterlaboratory.com/). The Exeter NIHR Clinical Research Facility coordinated sample storage and management. The sponsor of the study was the Royal Devon and Exeter NHS Foundation Trust. The South West Research Ethics committee approved the study (REC Reference: 12/SW/0323) in January 2013. SL is supported by a Wellcome GW4‐CAT fellowship (222850/Z/21/Z). NC acknowledges support from Crohn's & Colitis UK. We thank the patients who participated in the PANTS study, the Inflammatory Bowel Disease Pharmacogenetic Study Group, and research nurses who collected clinical data and biological samples at each study visit. We acknowledge the study co‐ordinators of the Exeter IBD Research Group, United Kingdom: Marian Parkinson and Helen Gardner‐Thorpe for their on‐going administrative support to the study."